Effects of canagliflozin in patients with type 2 diabetes and chronic heart failure: a randomized trial (CANDLE)

Effects of canagliflozin in patients with type 2 diabetes and chronic heart failure: a randomized trial (CANDLE)

Abstract Aims Little is known about the impact of sodium glucose co‐transporter 2 (SGLT2) inhibitors on cardiac biomarkers, such as natriuretic peptides, in type 2 diabetes (T2D) patients with concomitant chronic heart failure (CHF). We compared the effect of canagliflozin with glimepiride, based on...

Full description

Bibliographic Details
Main Authors: Atsushi Tanaka, Itaru Hisauchi, Isao Taguchi, Akira Sezai, Shigeru Toyoda, Hirofumi Tomiyama, Masataka Sata, Shinichiro Ueda, Jun‐ichi Oyama, Masafumi Kitakaze, Toyoaki Murohara, Koichi Node, CANDLE Trial Investigators
Format: Article
Language:English
Published: Wiley 2020-08-01
Series:ESC Heart Failure
Subjects:
Type 2 diabetes
Heart failure
SGLT2 inhibitor
NT‐proBNP
Non‐inferiority
Glimepiride
Online Access:https://doi.org/10.1002/ehf2.12707

Internet

https://doi.org/10.1002/ehf2.12707

Similar Items